Among the most clinically consequential single-nucleotide polymorphisms encountered in integrative and functional medicine practice is the COMT Val158Met (rs4680) variant. Catechol-O-methyltransferase (COMT) is the principal enzyme responsible for the metabolic degradation of catecholamines—dopamine, norepinephrine, and epinephrine—particularly within the prefrontal cortex, where dopamine transporter density is relatively sparse.1,2 Individuals homozygous for the Met allele (Met/Met, sometimes termed the “worrier” genotype) carry a COMT enzyme variant with approximately three- to four-fold lower catalytic activity compared to Val/Val homozygotes.3,4 While this confers certain cognitive advantages—enhanced working memory and executive function under baseline, low-stress conditions—it simultaneously creates vulnerability to catecholaminergic excess during periods of psychological or physiological stress. The clinical consequence is a characteristic phenotype: hyperarousal, heightened anxiety, difficulty with emotional regulation, and pronounced susceptibility to insomnia and sleep disruption.5 This article examines the molecular biochemistry underlying impaired COMT-mediated dopamine clearance and synthesizes the current evidence for targeted mitigation strategies, from methylation cofactor optimization to dietary modification and pharmacogenomic considerations.

You get a diagnosis. Maybe it's mast cell activation syndrome. Maybe it's fibromyalgia. Maybe it's long COVID. And you think — okay, now I know what I have. Now we treat it. But here's the thing most people don't hear: a diagnosis tells you what is happening. It doesn't always tell you why. In integrative medicine, we ask a different question. Not just — what do we call this? But — what got you here? What's keeping this active? Is there an underlying driver we haven't looked at yet? Take mast cell activation syndrome. Two patients can have the same diagnosis, but one was triggered by mold exposure, another by a post-viral immune shift. Same label. Completely different root paths. This doesn't mean we ignore your symptoms. We absolutely manage symptoms. But we also go deeper. We ask: what can we safely modify? What's driving the pattern? So if you've been diagnosed with something complex and you feel like you're only getting surface-level treatment — that's worth paying attention to. The label is useful. But the label is not the whole story.

Hydrogen sulfide small intestinal bacterial overgrowth — increasingly reclassified by leading gastroenterologists as Intestinal Sulfide Overproduction (ISO) — represents one of the most clinically challenging and underdiagnosed subtypes of gut dysbiosis. Unlike hydrogen-dominant SIBO (associated primarily with diarrhea) or methane-dominant SIBO/IMO (associated with constipation), ISO results from the unchecked proliferation of sulfate-reducing bacteria (SRBs) in the small intestine, producing hydrogen sulfide (H₂S) gas in pathological quantities. For decades, standard three-gas breath testing only measured hydrogen and methane, leaving ISO systematically invisible. The advent of the TrioSmart™ breath test (Gemelli Labs) — the first commercially available test to measure all three SIBO gases simultaneously — has finally given clinicians a diagnostic window into this condition. Even so, many patients with textbook ISO symptoms go years without a diagnosis, and formal treatment guidelines remain absent. This article synthesizes the current evidence base — including data presented at Digestive Disease Week (DDW) 2025 — to provide clinicians and informed patients with a practical, evidence-stratified approach to treating ISO/H₂S SIBO.

Do you have any thoughts about neurodivergence and chronic illness, chronic pain, have been reading about more, and treatment?

Histamine is a biogenic amine with essential physiological roles — it mediates immune responses, modulates gastric acid secretion, functions as a neurotransmitter, and participates in the regulation of circadian rhythms. Under normal conditions, the enzyme diamine oxidase (DAO) — produced primarily in the intestinal mucosa — efficiently catabolizes dietary histamine before it can accumulate to symptomatic levels. A second enzyme, histamine N-methyltransferase (HNMT), handles intracellular histamine degradation. Histamine intolerance (HIT) occurs when this enzymatic capacity is overwhelmed, most commonly due to impaired DAO activity, excessive dietary histamine load, or gut dysbiosis that tips the balance toward histamine-producing bacteria. The result is a broad and frustrating symptom constellation that can mimic allergic disease, irritable bowel syndrome, migraine, and autonomic dysfunction — while standard allergy testing returns negative. Mast cell activation syndrome (MCAS) represents an overlapping but distinct condition in which mast cells pathologically release histamine and other mediators in excess. Though the mechanisms differ from classic HIT, the dietary and probiotic strategies are largely parallel, and clinically the two conditions frequently coexist. This article summarizes the evidence-based framework for a low histamine diet and explores strain-specific probiotic considerations — an area of growing importance in integrative gastroenterology, integrative oncology, and functional immune care. https://www.ifmsynergy.com/the-low-histamine-diet-and-low-histamine-probiotics-a-practical-clinical-guide/